Dr Ed Wraith MB ChB, FRCPCH
Secretary
Christine Caveney
Tel: 0161 701 2137
Profile
Dr Wraith is a consultant paediatrician with the Willink Biochemical Genetics Unit, where he is responsible for the clinical and laboratory services provided by the unit. In addition, he is a pediatrician specializing in inherited metabolic diseases and, in particular, children with lysosomal storage disease. He directs the NCG-commissioned LSD service based at the Children's Hospital.
He was born in the north-east of England, graduated from Sheffield University in 1977 and received his postgraduate qualification in paediatrics (MRCP) in 1980. In 1993 he became a Fellow of the Royal College of Physicians (FRCP) and in 1997 a Fellow of the Royal College of Paediatrics and Child Health.
He has served on the editorial board of the Archives of Disease in Children and is an editor of The Journal of Inherited Metabolic Disease. Additionally, he is a medical advisor to UK Mucopolysaccharide Society and the Niemann-Pick Disease group.
Dr Wraith is currently researching several projects, including enzyme replacement therapy for the treatment of a number of lysosomal storage diseases and the use of substrate reduction therapy in patients with neurodegenerative disease.
He has written over 200 articles, abstracts, and book chapters on topics related to inborn errors of metabolism in neonates, children and adults.
Specialties
Lysosomal storage disorders
Publications
Arn P, Wraith E, Underhill L.
Characterization of surgical procedures in patients with mucopolysaccharidosis type I: Findings from the MPS I Registry.
J. Pediatr 2009;54:859-64.Wraith JE, Imrie J.
New therapies in the management of Niemann-Pick type C disease: clinical utility of miglustat.
Therapeutics and Clinical Risk Management 2009;5:877-887.Langford-Smith K, Arasaradnam M, Wraith JE, Wynn RF, Bigger B.
Evaluation of heparin cofactor II-thrombin complex as a biomarker on blood spots from mucopolysaccharidosis I, IIIA and IIIB mice.
Mol Genet Med 2009 (in press).Patterson MC, Vecchio D, Jacklin E, Abel L, Chadha-Boreham H, Luzy C, Giogino R, Wraith JE.
Long term Miglustat Therapy in Children with Niemann-Pick Disease Type C.
J Child Neurol 2009 (in press).Hsu AW, Piboolnurak PA, Floyd AG, Yu QP, Wraith JE, Patterson MC, Pullman SL.
Spiral analysis in Niemann-Pick disease type C.
Mov Disord 2009 (in press).Pineda M, Wraith JE, Mengel E, et al.
Miglustat in patients with Niemann-Pick Disease Type C (NP-C): a multicenter observational retrospective cohort study.
Mol Genet Med 2009;98:243-249.Malinowska M, Wilkinson FL, Bennett W, Langford-Smith K, O'Leary A, Jakobkiewicz-Banecka J, Wynn RF, Wraith JE, Bigger B.
Genistein reduces lysosomal storage in peripheral tissues of mucopolysaccharidosis type IIIB mice.
Mol Genet Metab 2009;98:235-242.Wynn RF, Wraith JE, Mercer J, et al.
Improved metabolic correction in patients with lysosomal storage disease treated with haematopoietic stem cell transplant compared with enzyme replacement therapy.
J. Pediatr 2009;154:609-611.Wraith JE, Guffon N, Rohrbach M, et al.
Natural history of Niemann-Pick disease type C in a multicentre, observational, retrospective cohort study.
Mol Genet Metab 2009;98:250-254.Jones SA, Almassy Z, Beck M, Burt K, Clarke JT, Guigliani R, Hendriksz C, Kroepfl T, Lavery L, Lin SP, Malm G, Ramaswami U, Tincheva R, Wraith JE.
Mortality and cause of death in mucopolysaccharidosis type II-a historical review based on data from the Hunter Outcome Survey (HOS).
J Inherit Metab Dis 2009;32:534-545.Wraith JE, Baumgartner MR, Bembi B, et al.
Recommendations on the diagnosis and management of Niemann-Pick disease type C.
Molecular Genetics and Metabolism 2009;98:152-165.Wynn RF, Stubbs M, Ozyilmaz N, Wraith JE, Bigger B.
Cellular therapy of lysosomal storage disorders: Current status and future prospects.
Current Paediatric Reviews 2009;5 (in press).Feldhammer M, Durand S, Mrázová L, Boucher RM, Laframboise R, Steinfeld R, Wraith JE, Michelakakis H, van Diggelen OP, Hrebícek M, Kmoch S, Pshezhetsky AV.
Sanfilippo syndrome type C: mutation spectrum in the heparan sulfate acetyl-CoA: alpha-glucosaminide N-acetyltransferase (HGSNAT) gene.
Hum Mutat 2009;30:918-925.Nicolino M, Bryne B, Wraith JE, Leslie N, et al.
Clinical outcomes after long term treatment with alglucosidase alfa in infants and children with advanced Pompe disease.
Genet Med 2009;11:210-219.Wynn RF, Mercer J, Page J, Jones S, Wraith JE.
Use of Enzyme Replacement Therapy (Laronidase) before Hematopoietic Stem Cell Transplantation for Mucopolysaccharidosis I: Experience in 18 patients.
J Pediatr 2009;154:135-139.Clarke LA, Wraith JE, Beck M, Kolodny EH, Pastores G, et al.
Long term efficacy and safety of Laronidase in the treatment of Mucopolysaccharidosis type I.
Pediatrics 2009;123:229-240.Muenzer J, Wraith JE, Clarke LA.
Mucopolysaccharidosis I: management and treatment guideline.
Pediatrics 2009;129:19-29.